Clinical Trial Search

Primary: Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups — 49; 44…

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 10.21; 10.2 joints smoked during the prior week — p=.99

Primary: Number of Participants With Gastric Ulcers — 7; 5; 7; 4 Participants

Primary: Catheter Related Pain: Visual Analog Score Rating — 2.67; 2.67 score on a scale

Primary: Dose-normalized Trough — 0.59; 0.44 ng/dL

Primary: Microbial Levels — 11; 7; 15; 15 Participants — p=0.35

Primary: Self-reported Medication Adherence From Baseline to 6 Months. — 80; 45; 59; 47 % of participants

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Urine 15-F2t Isoprostane Concentration — 2.7; 2.6 ng/mg Cr — p=0.88

Primary: ALS Functional Rating Scale-revised Version (ALSFRS-R) Slope — -0.39; -0.57 points per month — p=0.32

Primary: Pacing Mode Changes Between Permanent Pacemakers (PPMs)/Implantable Cardiac Defibrillators (ICDs) Scanned With RF Assure — 29; 29; 8; 8 participants — p=1.0

Primary: Change in HbA1c — -1.3; -0.9; -1.5; -0.9 Percentage-point of HbA1c — p=< 0.0001

Primary: Number of Participants Classified as Treatment Responders Within 12 Weeks — 59; 41 Participants

Primary: Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMG — -1.5; -1.9; -2.2 score on a scale — p=0.0118

Primary: Overall Response Rate — 0 Participants